Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Buys $27,864.00 in Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O’malley acquired 8,600 shares of Abeona Therapeutics stock in a transaction on Thursday, April 25th. The stock was purchased at an average cost of $3.24 per share, with a total value of $27,864.00. Following the completion of the transaction, the senior vice president now directly owns 188,718 shares in the company, valued at approximately $611,446.32. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Abeona Therapeutics Stock Performance

Shares of Abeona Therapeutics stock traded up $0.14 on Friday, hitting $3.33. The company’s stock had a trading volume of 352,578 shares, compared to its average volume of 429,769. Abeona Therapeutics Inc has a 1 year low of $2.83 and a 1 year high of $9.01. The firm has a fifty day moving average price of $7.37 and a 200-day moving average price of $5.63. The company has a market capitalization of $91.08 million, a price-to-earnings ratio of -1.26 and a beta of 1.49.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.13). As a group, analysts forecast that Abeona Therapeutics Inc will post -1.83 EPS for the current year.

Wall Street Analysts Forecast Growth

ABEO has been the topic of several recent research reports. StockNews.com lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $36.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Simplex Trading LLC raised its holdings in Abeona Therapeutics by 1,889.9% in the 3rd quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 13,418 shares during the last quarter. Jump Financial LLC purchased a new position in Abeona Therapeutics in the 4th quarter valued at about $199,000. Worth Venture Partners LLC raised its stake in shares of Abeona Therapeutics by 76.6% in the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 121,969 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Abeona Therapeutics in the 3rd quarter valued at about $648,000. Finally, Barclays PLC raised its stake in shares of Abeona Therapeutics by 100.0% in the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after purchasing an additional 185,638 shares in the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.